Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XmAb 819

Next Previous
Drug Profile

XmAb 819

Alternative Names: ENPP3 x CD3 - Xencor; XmAb 30819; XmAb-819

Latest Information Update: 11 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Renal cancer

Most Recent Events

  • 09 Sep 2024 Efficacy and adverse events data from a phase I trial in Renal cancer released by Xencor
  • 27 Jun 2022 Phase-I clinical trials in Renal cancer (Second-line therapy or greater) in USA (IV) (NCT05433142)
  • 11 Jan 2022 Xencor plans a phase I trial for Renal cancer in first half of 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top